SEC Form 3 · accession 0001209191-15-026608
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William T. Symonds
Officer — Chief Development Officer · Director
Period of report
Mar 4, 2015
Accepted (ET)
Mar 16, 2015 · 5:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 256,327 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person held 254,530 shares of common stock of OnCore Biopharma, Inc. ("OnCore"). Pursuant to that certain Agreement and Plan of Merger and Reorganization, dated January 11, 2015, by and among the issuer, TKM Acquisition Corporation and OnCore (the "Merger"), each issued and outstanding share of OnCore common stock was converted into 1.007062 common shares (rounded down) of the issuer. The closing of the Merger occurred on March 4, 2015.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney